Skip to main content

Table 1 Patient characteristics.

From: Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives

Patient

1

2

3

4

5

Patient age/disease discovery (year)

55

33

63

44

43

Primary disease date

April 1981

August 1985

January 1984

January 1997

August 1993

Primary disease location

Right ankle

Left calf

Left ankle

Left arm

Left thorax

Clarck index

III

V

IV

III

III

First recurrence date

March 1988

June 1986

April 1987

January 1997

March 1998

Previous treatment for advanced

disease (before cystemustine)

None

Dacarbazine Vindesine (6 cycles)

Dacarbazine Vinblastine (6 cycles)

Dacarbazine Interferon α 2a (6 cycles)

Interferon α 2a Radiotherapy

None

Dacarbazine (8 cycles)

Treatment start date

March 1988

May 1990

August 1990

February 1997

Novembre 1998

Custemustine dose (mg/m 2 )

90

60

90

90

60

Metastatic sites

Popliteal mass Lymph node

Lung Bone

Lymph node

Lymph node Sub-cutaneous

Lung

Treatment concomitant to Cystemustine

Surgery (March 1988)

None

None

None

None

Recurrence of the disease

None

None

None

None

None

Date of death

November 2000

Alive

March 2000

Alive

Alive

Disease free survival (years)

12

14

10

7

6